Lars Linden

This inventor holds 6 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Bayer Intellectual Property Gmbh, Bayer as, Bayer Pharma Aktiengesellschaft. Active years: 2015-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lars Linden. Retrieved from https://idiyas.com/inventor/lars-linden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 42(Granted Patents)

Location History:

Düsseldorf, DE (2015 - 2017)
Gevelsberg, DE (2021 - 2022)

Company Filing History:

3 out of 721

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

patents

4. 1 out of 200

Oklahoma Medical Research Foundation

patents

5. 1 out of 132

Seattle Genetics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11260136 - Radio-pharmaceutical complexes (2022-03-01),

2. 11077187 - Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof (2021-08-03),

3. 9777063 - Neutralizing prolactin receptor antibody Mat3 and its therapeutic use (2017-10-03),

4. 9382305 - Relaxin fusion polypeptides and uses thereof (2016-07-05),

5. 9353186 - Neutralizing prolactin receptor antibody Mat3 and its therapeutic use (2016-05-31),

6. 8992932 - Binder-drug conjugates (ADCs) and use thereof (2015-03-31),

Title: Lars Linden: Innovator in Radio-pharmaceuticals and Monoclonal Antibodies

Introduction

Lars Linden is a notable inventor based in Düsseldorf, Germany. He has made significant contributions to the fields of radio-pharmaceuticals and monoclonal antibodies. With a total of 6 patents to his name, his work has the potential to impact medical treatments significantly.

Latest Patents

Linden's latest patents include innovative methods for creating tissue-targeting thorium complexes. This invention outlines a method that involves forming an octadentate chelator with specific moieties and coupling it to a tissue-targeting moiety that targets HER2. Additionally, he has developed a method for treating neoplastic or hyperplastic diseases using these thorium complexes. Another significant patent involves optimized humanized monoclonal antibodies that selectively bind to activated protein C, providing new avenues for treatment without affecting unactivated protein C.

Career Highlights

Throughout his career, Lars Linden has worked with prominent companies such as Bayer Intellectual Property GmbH and Seattle Genetics, Inc. His experience in these organizations has allowed him to refine his expertise in the development of innovative medical solutions.

Collaborations

Linden has collaborated with notable professionals in his field, including Andreas Wilmen and Christoph Freiberg. These partnerships have contributed to the advancement of his research and inventions.

Conclusion

Lars Linden's contributions to the fields of radio-pharmaceuticals and monoclonal antibodies demonstrate his commitment to innovation in medical science. His patents reflect a deep understanding of complex biological interactions and a dedication to improving treatment options for patients.

Profile summary based on public USPTO records.